Cargando…

Economic study of the value of expanding HCV treatment capacity in Germany

BACKGROUND: Today's highly efficacious, low-toxicity interferon-free treatment regimens for chronic hepatitis C virus (HCV) can cure most patients with HCV in 12–24 weeks. The aim of this study was to understand how the introduction of shorter duration treatment regimens for HCV will impact the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sbarigia, Urbano, Wirth, Daniel, Van Nuys, Karen, Huber, Caroline, Brookmeyer, Ron, Stahmeyer, Jona, Krauth, Christian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2017
Materias:	Hepatology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5387957/ https://www.ncbi.nlm.nih.gov/pubmed/28461903 http://dx.doi.org/10.1136/bmjgast-2016-000130

Ejemplares similares

Cost-effectiveness of Triple Therapy with Telaprevir for Chronic Hepatitis C Virus Patients in Germany
por: Stahmeyer, Jona T., et al.
Publicado: (2013)

Elimination of hepatitis C virus in Germany: modelling the cost-effectiveness of HCV screening strategies
por: Krauth, Christian, et al.
Publicado: (2019)

Defining the key intrahepatic gene networks in HCV infection driven by sex
por: Marchi, Emanuele, et al.
Publicado: (2023)

HVR1-mediated antibody evasion of highly infectious in vivo adapted HCV in humanised mice
por: Prentoe, Jannick, et al.
Publicado: (2016)

Effectiveness and safety of sofosbuvir plus ribavirin for the treatment of HCV genotype 2 infection: results of the real-world, clinical practice HCV-TARGET study
por: Welzel, Tania M, et al.
Publicado: (2017)

Additive effects of HLA alleles and innate immune genes determine viral outcome in HCV infection
por: Fitzmaurice, Karen, et al.
Publicado: (2015)

Cost-Effectiveness of Treating Hepatitis C with Sofosbuvir/Ledipasvir in Germany
por: Stahmeyer, Jona T., et al.
Publicado: (2017)

Host cell mTORC1 is required for HCV RNA replication
por: Stöhr, Stefanie, et al.
Publicado: (2016)

Comparison of tools for assessing the methodological quality of primary and secondary studies in health technology assessment reports in Germany
por: Dreier, Maren, et al.
Publicado: (2010)

Hyperbilirubinaemia in HIV–HCV co-infected patients on antiretroviral therapy: drug effect or liver disease severity?
por: Kaspar, Matthew B, et al.
Publicado: (2016)

HCV genome-wide analysis for development of efficient culture systems and unravelling of antiviral resistance in genotype 4
por: Pham, Long V., et al.
Publicado: (2022)

Reduced fibrosis in recurrent HCV with tacrolimus, azathioprine and steroids versus tacrolimus: randomised trial long term outcomes
por: Manousou, Pinelopi, et al.
Publicado: (2014)

Characterisation of liver pathogenesis, human immune responses and drug testing in a humanised mouse model of HCV infection
por: Keng, Choong Tat, et al.
Publicado: (2016)

Humanisation of a claudin-1-specific monoclonal antibody for clinical prevention and cure of HCV infection without escape
por: Colpitts, Che C, et al.
Publicado: (2018)

Extracellular lipid-free apolipoprotein E inhibits HCV replication and induces ABCG1-dependent cholesterol efflux
por: Crouchet, Emilie, et al.
Publicado: (2017)

Novel host genetic variations associated with spontaneous clearance of a single-source outbreak of HCV1b infections
por: You, Hong, et al.
Publicado: (2015)

The broad assessment of HCV genotypes 1 and 3 antigenic targets reveals limited cross-reactivity with implications for vaccine design
por: von Delft, Annette, et al.
Publicado: (2016)

Chimeric antigen receptor (CAR)-engineered T cells redirected against hepatitis C virus (HCV) E2 glycoprotein
por: Sautto, Giuseppe A, et al.
Publicado: (2016)

Modulation of HCV reinfection after orthotopic liver transplantation by fibroblast growth factor-2 and other non-interferon mediators
por: Van, Nguyen Dinh, et al.
Publicado: (2016)

Inactivated genotype 1a, 2a and 3a HCV vaccine candidates induced broadly neutralising antibodies in mice
por: Alzua, Garazi Pena, et al.
Publicado: (2023)

Remaining challenges in HCV elimination
por: Capraru, Camelia, et al.
Publicado: (2021)

miR-135a-5p-mediated downregulation of protein tyrosine phosphatase receptor delta is a candidate driver of HCV-associated hepatocarcinogenesis
por: Van Renne, Nicolaas, et al.
Publicado: (2018)

Ledipasvir/sofosbuvir with or without ribavirin for 8 or 12 weeks for the treatment of HCV genotype 4 infection: results from a randomised phase III study in Egypt
por: Shiha, Gamal, et al.
Publicado: (2019)

Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort
por: Welzel, Tania M, et al.
Publicado: (2016)

Suppressor CD4(+) T cells expressing HLA-G are expanded in the peripheral blood from patients with acute decompensation of cirrhosis
por: Khamri, Wafa, et al.
Publicado: (2022)

Resource Utilisation and Costs of Depressive Patients in Germany: Results from the Primary Care Monitoring for Depressive Patients Trial
por: Krauth, Christian, et al.
Publicado: (2014)

Updated upper limit of normal for serum alanine aminotransferase value in Vietnamese population
por: Huong, Nguyen Thi Cam, et al.
Publicado: (2022)

Value and risk of percutaneous liver biopsy in patients with cirrhosis and clinical suspicion of autoimmune hepatitis
por: Sripongpun, Pimsiri, et al.
Publicado: (2021)

Serum aminotransferase ratio is independently correlated with hepatosteatosis in patients with HCV: a cross-sectional observational study
por: Lin, Ming-Shyan, et al.
Publicado: (2015)

Village-to-village screening for hepatitis B and C using quantitative HBsAg and anti-HCV testing with reflex HCV core antigen tests in the remote communities of a resource-rich setting: a population-based prospective cohort study
por: Chang, Te-Sheng, et al.
Publicado: (2021)

Assessing the impact of simplified HCV care on linkage to care amongst high-risk patients at primary healthcare clinics in Malaysia: a prospective observational study
por: Markby, Jessica, et al.
Publicado: (2021)

Viusid, a nutritional supplement, increases survival and reduces disease progression in HCV-related decompensated cirrhosis: a randomised and controlled trial
por: Vilar Gomez, Eduardo, et al.
Publicado: (2011)

Evaluation of published assessment tools for comorbidity in liver transplantation: a systematic review protocol
por: Qu, Zhi, et al.
Publicado: (2018)

Molecular footprints reveal the impact of the protective HLA-A*03 allele in hepatitis C virus infection
por: Fitzmaurice, Karen, et al.
Publicado: (2011)

Economic burden of cirrhosis in Catalonia: a population-based analysis
por: Miquel, Mireia, et al.
Publicado: (2018)

Value-based care pathway for inflammatory bowel disease: a protocol for the multicentre longitudinal non-randomised parallel cluster IBD Value study with baseline period
por: van Linschoten, Reinier Cornelis Anthonius, et al.
Publicado: (2022)

Oncolytic reovirus as a combined antiviral and anti-tumour agent for the treatment of liver cancer
por: Samson, Adel, et al.
Publicado: (2018)

S100A10 promotes HCC development and progression via transfer in extracellular vesicles and regulating their protein cargos
por: Wang, Xia, et al.
Publicado: (2023)

Trial protocol: a randomised controlled trial to verify the non-inferiority of a partially covered self-expandable metal stent to an uncovered self-expandable metal stent for biliary drainage during neoadjuvant therapy in patients with pancreatic cancer with obstructive jaundice (PUN-NAC trial)
por: Kuwatani, Masaki, et al.
Publicado: (2021)

Safety and tolerability of a single infusion of autologous ex vivo expanded regulatory T cells in adults with ulcerative colitis (ER-TREG 01): protocol of a phase 1, open-label, fast-track dose-escalation clinical trial
por: Voskens, Caroline J, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_6f9baa11gah909ln1vpprh3las